SLC20A1

Across TCGA pan-cancer cohorts, SLC20A1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SLC20A1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SLC20A1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC20A1 is over-expressed in tumor.

CCRCC, HNSC, and PDAC are the cancer types where SLC20A1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC20A1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.687	<.001	8	view →
HNSC	All	All	+0.638	.003	8	view →
PDAC	Male	II,III,IV	+1.031	.017	3	view →
LUAD	Male	All	+0.240	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

SLC20A1–CCRCC

Open the CCRCC breakdown →